PCS-2023 > X > XW > XW0 > XW01 |
XW0 | Anatomical Regions, Introduction | |
Info: | Introduction: Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products | |
XW01 | Introduction, Subcutaneous Tissue | |
XW013 | Percutaneous | |
XW0131 | Daratumumab and Hyaluronidase-fihj | |
XW01318 | Introduction of Daratumumab and Hyaluronidase-fihj into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8 | |
XW0134 | Teclistamab Antineoplastic | |
XW01348 | Introduction of Teclistamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8 | |
XW0139 | Satralizumab-mwge | |
XW01397 | Introduction of Satralizumab-mwge into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7 | |
XW013F | Other New Technology Therapeutic Substance | |
XW013F5 | Introduction of Other New Technology Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5 | |
XW013H | Other New Technology Monoclonal Antibody | |
XW013H6 | Introduction of Other New Technology Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 | |
XW013K | Leronlimab Monoclonal Antibody | |
XW013K6 | Introduction of Leronlimab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 | |
XW013S | COVID-19 Vaccine Dose 1 | |
XW013S6 | Introduction of COVID-19 Vaccine Dose 1 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 | |
XW013T | COVID-19 Vaccine Dose 2 | |
XW013T6 | Introduction of COVID-19 Vaccine Dose 2 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 | |
XW013U | COVID-19 Vaccine | |
XW013U6 | Introduction of COVID-19 Vaccine into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 | |
XW013V | COVID-19 Vaccine Dose 3 | |
XW013V7 | Introduction of COVID-19 Vaccine Dose 3 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7 | |
XW013W | Caplacizumab | |
XW013W5 | Introduction of Caplacizumab into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5 | |
XW013W7 | Introduction of COVID-19 Vaccine Booster into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7 | |
XW01X | External | |
XW01X2 | Bromelain-enriched Proteolytic Enzyme | |
XW01X27 | Introduction of Bromelain-enriched Proteolytic Enzyme into Subcutaneous Tissue, External Approach, New Technology Group 7 |
ICD-10-CM-2023 Code Search Engine and PCS-2023 Code Search Engine |